Back to Condition
CLN7 disease
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

CLN7 disease

CLN7 disease is an inherited disorder that primarily affects the nervous system, leading to a decline in mental and motor skills.

Overview

CLN7 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms of this condition typically begin between ages 2 and 7. The initial features are usually vision loss and problems with movement that might seem like clumsiness. Additional signs and symptoms of CLN7 disease include muscle twitches (myoclonus), difficulty coordinating movements (ataxia), recurrent seizures (epilepsy), and speech impairment. Mental functioning and motor skills (such as sitting and walking) decline with age. Individuals with CLN7 disease typically do not survive past their teens.

CLN7 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation "CLN," meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.

Frequency

The incidence of CLN7 disease is unknown; more than 70 cases have been described in the scientific literature. CLN7 disease was first diagnosed in the Turkish population and was thought to be limited to individuals in that group. However, CLN7 disease has now been identified in people around the world. Collectively, all forms of NCL affect an estimated 1 in 100,000 individuals worldwide.

Causes

Mutations in the MFSD8 gene cause CLN7 disease. The MFSD8 gene provides instructions for making a protein whose function is unknown. The MFSD8 protein is embedded in the membrane of cell compartments called lysosomes, which digest and recycle different types of molecules. Based on the structure of the protein, MFSD8 probably transports molecules across the lysosomal membrane, but the specific molecules it moves have not been identified.

MFSD8 gene mutations likely lead to the production of a protein with altered structure or function. It is unclear how an altered MFSD8 protein leads to the severe neurological features of CLN7 disease. CLN7 disease, like other NCLs, is characterized by the accumulation of proteins and other substances in lysosomes. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. These accumulations can cause cell damage leading to cell death. Individuals with CLN7 disease have gradual nerve cell loss in certain parts of the brain, which likely leads to the signs and symptoms of this condition.

Gene associated with CLN7 disease

  • MFSD8

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • CLN7
  • CLN7 disease, late infantile
  • MFSD8-related neuronal ceroid lipofuscinosis

Frequently Asked Questions

Parents should watch for progressive vision loss, clumsiness or difficulty with coordination, sudden muscle twitches (myoclonus), early speech delays, and the first signs of seizures. If several of these symptoms appear between ages 2 and 7, a neurologist should be consulted.
Diagnosis is confirmed by genetic testing that identifies pathogenic variants in the MFSD8 gene. Additional evaluations include an EEG to detect seizure activity, visual evoked potentials to assess optic nerve function, and MRI or CT scans to look for brain changes.
Current management is supportive: antiepileptic drugs for seizures, physical and occupational therapy for motor skills, and vision aids. Experimental gene‑replacement therapies are in early clinical trials, and patients may consider enrolling in research studies.
Most individuals do not survive beyond their teens. Palliative care focuses on pain control, seizure management, nutritional support, and psychosocial counseling. Early referral to a hospice or palliative care team can help maintain comfort and quality of life.===
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab